phenylalanine and Blast Phase

phenylalanine has been researched along with Blast Phase in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ameye, G; Constantinescu, SN; Demoulin, JB; Duhoux, FP; Herman, M; Iossifidis, S; Lambert, C; Libouton, JM; Poirel, HA1
Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N1
Rosenfeld, CS1

Other Studies

3 other study(ies) available for phenylalanine and Blast Phase

ArticleYear
Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells.
    Leukemia research, 2012, Volume: 36, Issue:1

    Topics: Aged, 80 and over; Amino Acid Substitution; Base Sequence; Blast Crisis; Cell Cycle Proteins; Gene Fusion; Histone-Lysine N-Methyltransferase; Humans; Janus Kinase 2; Male; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Phenylalanine; Polymorphism, Single Nucleotide; RNA-Binding Proteins; Sequence Inversion; Thrombocythemia, Essential; Valine

2012
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Adult; Antineoplastic Agents; Blast Crisis; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure

2006
Antileukemic activity of phenylalanine methyl ester (PME): a lysosomotropic peptide methyl ester.
    Stem cells (Dayton, Ohio), 1994, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Child; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monocytes; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temperature; Tumor Cells, Cultured

1994